Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France

Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France

Bibliographic Details
Main Authors:	P. Barthélémy, A. Thiery-Vuillemin, B. Escudier, J-C. Eymard, G. Mouillet, F. Schlürmann, M. Chartier, C. Quentric, Y-A. Vano, L. Albiges
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320362303

Similar Items

IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany
by: A. Thiery-Vuillemin, et al.
Published: (2020-11-01)

Nivolumab in renal cell carcinoma: latest evidence and clinical potential
by: Camille Mazza, et al.
Published: (2017-03-01)

ARCC network: Annual Report 2016
by: Street, R
Published: (2016)

ARCC network: A blog about blogging
by: Wilkins, T
Published: (2016)

Nephrectomy after complete response to immune checkpoint inhibitors for metastatic Renal Cell Carcinoma (mRCC): A new surgical challenge?
by: G. Pignot, et al.
Published: (2020-07-01)

ARCC network blog: Taking it to the streets – mainstreaming research
by: Wilkins, T
Published: (2016)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
by: Giuseppe Procopio, et al.
Published: (2022-11-01)

Adaptation and resilience in the context of change (ARCC) network annual report 2014
by: Street, R, et al.
Published: (2015)

Adaptation and Resilience in the Context of Change (ARCC) Network Annual Report 2015
by: ARCC Network
Published: (2015)

Lessons from coordinating a knowledge exchange network. A report from the ARCC network
by: I, C
Published: (2016)

ARCC network blog: You call it networking – I call it ‘casual stalking’…
by: Wilkins, T
Published: (2017)

Adaptation and Resilience in a Changing Climate (ARCC) network. Annual report 2017
by: Street, R
Published: (2018)

ARCc: A case for an architecturally redundant cache-coherence architecture for large multicores
by: Khan, Omer, et al.
Published: (2012)

Living with our buildings and infrastructure: adapting for the future. ARCC network research update 2012
by: Street, R
Published: (2012)

Collaborative research for a changing climate: learning from researchers and stakeholders in the ARCC programme.
by: Lonsdale, K, et al.
Published: (2012)

Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal-Cell Carcinoma) study
by: Simona de Portu, et al.
Published: (2009-06-01)

ARCC network checklist for authors: Six things to do when you submit an article for publication
by: Hewer, F
Published: (2015)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
by: Joanna Bialek, et al.
Published: (2022-12-01)

Conce pts of statistical inference/
by: 216135 Guenther, William C.
Published: (1973)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
by: S. Opat, et al.
Published: (2022-06-01)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
by: Moshe C. Ornstein, et al.
Published: (2019-05-01)

RCC dams in 2008/
by: 307327 Dunstan, M. R. H., et al.

Taking advantage of RCC/
by: Warren, Ted, et al.

Remaja@pts one 2008 /
by: Nurismaliza Ismail, editor
Published: (2008)

Investigating the impact of open label design on patient‐reported outcome results in prostate cancer randomized controlled trials
by: Guillaume Mouillet, et al.
Published: (2020-10-01)

Recent developments in RCC dams/
by: 307327 Dunstan, M. R. H., et al.

Modification of Earth Dam by RCC
by: 韦卓信
Published: (2000-01-01)

Open Surgery for Localized RCC
by: Kathy Vander Eeckt, et al.
Published: (2007-01-01)

40 años de RCC
by: Brenda Carranza
Published: (2020-10-01)

Who witnesses the witness? Finding witnesses in the witness is hard and sometimes impossible
by: Abel, Zachary R, et al.
Published: (2020)

Who witnesses The Witness? Finding witnesses in The Witness is hard and sometimes impossible
by: Abel, Zachary R, et al.
Published: (2020)

Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
by: Aurélien Marabelle, et al.
Published: (2025-01-01)

Cholesterol accumulation in ccRCC: the role of ccRCC-initiating VHL-HIFα pathway
by: M. Aiman Mohtar, et al.
Published: (2024-05-01)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
by: Xiaoyan Liu, et al.
Published: (2019-07-01)

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
by: Yan Lin, et al.
Published: (2023-10-01)

Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma
by: Lisa Derosa, et al.
Published: (2016-11-01)

RCC dam construction : a contractor's view/
by: Roller compacted concrete III : (3rd conference : preprints), et al.

Implementasi Knowledge Management pada KLPM-PTS: Pembentukan Sharing Culture antar Anggota KLPM-PTS di Indonesia
by: Maryani Maryani
Published: (2012-06-01)

Expert witness
by: S C Parakh
Published: (2011-01-01)

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
by: Luigi Liguori, et al.
Published: (2023-11-01)